Research Department, The Infectious Diseases Institute Limited, Makerere University, Kampala, Uganda.
Department of Global Health, University of Washington, Seattle, WA.
J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):125-132. doi: 10.1097/QAI.0000000000003471.
BACKGROUND: Peer-delivered HIV self-testing (HIVST) and sexually transmitted infection self-sampling (STISS) may promote adherence to oral pre-exposure prophylaxis (PrEP), but no studies have analyzed this approach among transgender women (TGW) in sub-Saharan Africa. SETTING: The Peer study was a cluster randomized trial in Uganda (October 2020-July 2022; NCT04328025). METHODS: Ten TGW peer groups, each with 1 TGW peer and 8 TGW, were randomized 1:1 to receive quarterly in-clinic HIV testing with PrEP refills as standard-of-care (SOC) or SOC plus monthly peer delivery of oral-fluid HIVST, STISS, and PrEP refills (intervention). Participants were followed for 12 months. The primary outcome was PrEP adherence. RESULTS: We screened 85 TGW and enrolled 82 (41 per arm). The median age was 22 years (interquartile range [IQR] 20-24). Twelve-month retention was 88% (72/82). At the 3, 6, 9, and 12-month clinic visits, 10%, 5%, 5%, and 0% of TGW in the intervention arm had TFV-DP levels ≥700 fmol/punch, versus 7%, 15%, 7%, and 2% in the SOC arm, respectively (P = 0.18). At all visits, any detectable TFV-DP levels were significantly higher in SOC than the peer delivery group (P < 0.04). PrEP adherence was associated with sex work (incidence rate ratio 6.93; 95% CI: 2.33 to 20.60) and >10 years of schooling (incidence rate ratio 2.35; 95% CI: 1.14 to 4.84). There was a strong correlation between tenofovir detection in dried blood spots and urine (P < 0.001). No HIV seroconversions occurred. CONCLUSIONS: Peer-delivered HIVST and STISS did not increase low levels of oral PrEP adherence among TGW in Uganda. Long-acting PrEP formulations should be considered for this population.
背景:同伴提供的艾滋病毒自检(HIVST)和性传播感染自检(STISS)可能会促进口服暴露前预防(PrEP)的依从性,但在撒哈拉以南非洲的跨性别女性(TGW)中,尚无研究分析这种方法。
地点:Peer 研究是在乌干达进行的一项集群随机试验(2020 年 10 月至 2022 年 7 月;NCT04328025)。
方法:10 个 TGW 同伴小组,每个小组有 1 个 TGW 同伴和 8 个 TGW,按照 1:1 的比例随机分配接受每季度在诊所进行的 HIV 检测和 PrEP 补充作为标准护理(SOC)或 SOC 加每月由同伴提供的口服液 HIVST、STISS 和 PrEP 补充(干预)。参与者随访 12 个月。主要结局是 PrEP 依从性。
结果:我们共筛查了 85 名 TGW 并招募了 82 名(每组 41 名)。中位年龄为 22 岁(四分位间距 [IQR] 20-24)。12 个月的保留率为 88%(72/82)。在第 3、6、9 和 12 个月的诊所就诊时,干预组中有 10%、5%、5%和 0%的 TGW 的 TFV-DP 水平≥700fmol/点,而 SOC 组分别为 7%、15%、7%和 2%(P=0.18)。在所有就诊时,SOC 组的任何可检测 TFV-DP 水平均明显高于同伴提供组(P<0.04)。PrEP 依从性与性工作(发病率比 6.93;95%CI:2.33 至 20.60)和>10 年受教育年限(发病率比 2.35;95%CI:1.14 至 4.84)相关。在干血斑和尿液中检测到的替诺福韦之间存在很强的相关性(P<0.001)。未发生 HIV 血清转换。
结论:在乌干达,同伴提供的 HIVST 和 STISS 并未增加 TGW 中低水平的口服 PrEP 依从性。应考虑为该人群提供长效 PrEP 制剂。
Lancet HIV. 2022-10
J Acquir Immune Defic Syndr. 2022-4-1